Over the coming weeks on Oncology Central we will be carrying out a Spotlight event on cancer and the immune system. This Spotlight will aim to review the intricacies of how cancer cells and immune cells interact, look at the escape mechanisms that cancers employ to evade an antitumor immune response and explore the story behind some of the novel immunotherapy agents that have been developed to reverse this immune evasion.
Additionally, we will look at successes so far for this therapy modality – most notably, immune checkpoint inhibition. After demonstrating successes in advanced melanoma and other disease areas, what is next for these agents? How could treatment with checkpoint inhibitors be optimized and personalized?
We will also explore immunotherapy beyond targeting PD-L1 and other immune checkpoint proteins. What could be the role of cancer vaccines, cell therapies and other innovative agents?
This spotlight will feature key features from the MEDLINE-indexed journal Immunotherapy, and exclusive interviews and features with key opinion leaders in the field.
Below you can find information on all the content associated with this Spotlight – we’ll be adding to it frequently, so be sure to keep checking back.
Immune checkpoint inhibition
Other emerging immunotherapeutic strategies
Recent immunotherapy headlines
- Analysis favors immunotherapy for advanced melanoma
- Diversity of gut bacteria linked with response to immunotherapy in melanoma
- Pembrolizumab shows therapeutic potential in non-small-cell lung cancer
- Atezolizumab significantly improves lung cancer survival vs standard chemotherapy in Phase III trial
- Melanoma brain metastases: promising results for immune and targeted therapies combined with radiosurgery
- Effectiveness of four PD-L1 tests compared
- Promising results demonstrated for CAR-T therapy in advanced non-Hodgkin lymphoma patients
- Prolonging the survival of advanced pancreatic cancer patients with a novel immunotherapy drug
- Combination immunotherapy–chemotherapy may help eliminate dormant tumor cells